



HIP-Vax[®]: Low-cost viral vector manufacturing

“Our novel HIP-Vax platform combines several technological innovations to reduce cost and speed up viral vector product manufacturing”, says Wilfried Bakker, Director of Science and Innovation at Batavia Biosciences.

Benefits of HIP-Vax

- Suitable for gene therapy, oncolytic virotherapy and vector vaccines
- Reduces time from bench to clinic to 9 months including product release
- Vaccines Cost of Goods <\$1.00 per dose, based on fully loaded cost model (including labor, consumables, capital charge, fill & finish, testing)
- 1000L output in 50-100L harvest volume
- High cell density for adherent and suspension cell culture
- Concentrated harvest opens possibilities for new product delivery technologies
- Excellent scalability: from R&D to clinical and commercial scale
- Proven qualified under cGMP conditions

Available Vaccine Protocols

Process description, analytical methods, and cGMP documentation available for the following products.

- Polio vaccine (Sabin, inactivated)
- Polio vaccine (oral)
- Measles vaccine (Edmonston-Zagreb)
- Rubella (Strain RA27/3)

Biological Materials Available under SIDUS[®] brand strengthens HIP-Vax

- Vaccine seeds (R&D & GMP grade)
- Cell substrates (R&D & GMP grade)
- Viral vector systems (R&D & GMP grade)

Licensing

Fee upon provision of materials; Recurring payments every 4 years.

Fee upon provision of know-how file: milestone payments at start clinical development.

HIP-Vax: Novel viral vector production technology



HIP-Vax[®] delivers

- Robust, intensified manufacturing platform
- Low Cost of Goods
- Reduced risk of batch failure
- Small manufacturing footprint
- Reduced bioprocessing timelines

for more information: www.bataviabiosciences.com